TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03240601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation
Description: For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous spinal stimulation
Description: For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
Study: NCT03589716

Intervention type: OTHER
Group type: OTHER
Intervention: Vital Moto Mod
Description: All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.

Intervention type: OTHER
Group type: OTHER
Intervention: Vital Moto Mod
Description: All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.

Intervention type: OTHER
Group type: OTHER
Intervention: Welch Allyn Connex Spot Vital Signs Monitor
Description: This is the FDA approved reference device to measure heart rate, SpO2 and temperature.

Intervention type: OTHER
Group type: OTHER
Intervention: Welch Allyn Connex Spot Vital Signs Monitor
Description: This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
Study: NCT03235284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Wii
Description: Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises and Nintendo Wii
Description: In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
Study: NCT03476707

Intervention type: OTHER
Intervention: Anemia
Description: Hematocrit less than 0.39
Study: NCT01051830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes interdisciplinary program
Description: Diabetes consulting, rehabilitation program
Study: NCT00201890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)
Description: 20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
Study: NCT02898415

Intervention type: PROCEDURE
Intervention: Liver transplantation
Study: NCT01277900

Intervention type: PROCEDURE
Intervention: Laparoscopic Roux en Y gastric Bypass
Description: Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
Study: NCT03589716

Intervention type: OTHER
Group type: OTHER
Intervention: Capnostream 20 Portable Bedside Capnograph
Description: This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Capnostream 20 Portable Bedside Capnograph
Description: This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope
Description: These reference devices will be used together for blood pressure measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope
Description: These reference devices will be used together for blood pressure measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Scifit 1000R cycle ergometer
Description: This is the device that will be used for exercise testing
Study: NCT01404741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation
Description: donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
Study: NCT02111187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225
Description: Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
Study: NCT01404741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5-azacytidine until progress
Description: if no donor available 5-azacytidine until progress or toxicities
Study: NCT03264404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 50 mg/m2 subcutaneous daily for 5 days every 28 days
Study: NCT00904969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AMS Male Transobturator Sling System
Description: The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdVance Male Sling
Description: A transobturator sling for the treatment of post-prostatectomy incontinence
Study: NCT04267354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm cycling
Description: The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
Study: NCT01843829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
Study: NCT01910285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanyl - sufentanil placebo
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil - remifentanyl placebo
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
Study: NCT02137746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa Experimental therapy
Study: NCT03074136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodinamic therapy
Description: Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Sodium hypochlorite
Description: Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Sodium hypochlorite
Description: Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Sodium hypochlorite
Description: Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
Study: NCT02473848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate 500 ucg
Description: Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
Study: NCT00603408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy
Description: (RECOMMENDED BUT NOT REQUIRED)
Study: NCT04985617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed Fluids
Description: The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
Study: NCT04762121

Intervention type: PROCEDURE
Intervention: Peripheral IV
Description: Insertion of peripheral intravenous catheter
Study: NCT04847193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 1: Placebo
Description: Participants receive a study drink supplemented with a placebo for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Description: Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Description: Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
Study: NCT01221896

Intervention type: PROCEDURE
Intervention: C11-Choline PET/CT
Study: NCT04450238

Intervention type: BEHAVIORAL
Intervention: Routine care inpatient treatment
Description: All participants are receiving inpatient treatment consisting of a variety of psychological interventions such as cognitive-behavioral therapy, third-wave interventions, psycho-education and in some cases medication.
Study: NCT00425269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention (diet and physical activity)
Description: The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
Study: NCT01140529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Bolus and continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Bolus doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bolus and continuous infusion
Study: NCT00281463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pushrim Activated Power Assist
Description: The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
Study: NCT03544749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Description: After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
Study: NCT05165134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Elastic tape used for mechanical correction of the deformity in study group and placebo in control group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotape
Description: Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
Study: NCT01423175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine, ara-C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAMSA
Study: NCT04456504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine with CpG adjuvant
Description: Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
Study: NCT01703910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arm B chemotherapy
Study: NCT01666249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Anti-RhD
Description: Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
Study: NCT03011918

Intervention type: OTHER
Intervention: Data Collection prior to first fall for all fallers
Description: Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected

Intervention type: OTHER
Intervention: Data Collection prior to first fall for all fallers
Description: Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected

Intervention type: OTHER
Intervention: Hgb value
Description: Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected

Intervention type: OTHER
Intervention: Hgb value
Description: Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected

Intervention type: OTHER
Intervention: Vitamin D
Description: Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..

Intervention type: OTHER
Intervention: Vitamin D
Description: Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..

Intervention type: OTHER
Intervention: C-Reactive Protein
Description: Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.

Intervention type: OTHER
Intervention: C-Reactive Protein
Description: Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
Study: NCT00568295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rofecoxib
Description: Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rofecoxib
Description: Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Study: NCT04901793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset and handheld remote control.
Description: Brand name: Oculus Quest
Study: NCT02849418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1358820
Description: GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection contains sodium chloride (0.9 milligrams \[mg\]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
Study: NCT02249663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride and Fluticasone propionate
Description: 137/50 mcg Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dymista™
Description: 137/50 mcg Nasal Spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray with no pharmaceutically active content
Study: NCT04410900

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wistar Rabies Virus Strain PM-1503-3M Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wistar Rabies Virus Strain PM-1503-3M Vaccine
Description: Given IM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT00144547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg(i.v.)/4weeks
Study: NCT00671294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and Placebo (9 possible combinations total)
Description: Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights
Study: NCT02821234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI